<DOC>
	<DOCNO>NCT00294463</DOCNO>
	<brief_summary>Tibolone , tissue-selective compound combination estrogenic , progestogenic androgenic property , use alternative estrogen estrogen plus progesterone hormone therapy treatment symptom associate menopause osteoporosis . The current study compare endometrial histology , biochemistry ( hormone level ) gene-expression profile short-term ( 21-days ) treatment tibolone , finding treatment estradiol-only ( E2 ) E2+Medroxyprogesterone Acetate ( MPA ) healthy postmenopausal woman undergo hysterectomy endometrial prolaps . Since short-term tibolone use result increase spot bleed long-term treatment tibolone show lead atrophic endometrium hypothesis tibolone first display estrogenic mode action , time , counterbalance tibolone 's progestagenic property</brief_summary>
	<brief_title>Effects Tibolone Treatment Endometrium</brief_title>
	<detailed_description>Effects estrogen deficiency woman climacteric symptom bone loss , efficiently treat substitute estrogen ( 1 ) . Unopposed estrogen treatment , however , increase risk endometrial hyperplasia subsequent carcinoma . For example HOPE study ( Women ’ Health , Osteoporosis , Progestin , Estrogen study ( 2 , 3 ) ) , two year treatment conjugate equine estrogen ( 0.625mg/day CEE ) rate hyperplasia go 27,7 % . When treatment combine MPA ( 2.5 mg ) incidence hyperplasia completely disappear . Thus , addition progestagens necessary endometrial safety . Progestagen addition ( continuous combine estrogen plus progestin therapy ) , however , also cause negative side effect like withdrawal bleeding increase breast cancer incidence recently document Women ’ Health Initiative ( 4 ) Million Women Study ( 5 ) . Tibolone tissue-specific compound use treatment climacteric complaint prevention osteoporosis stimulate endometrium like estrogen ( 6 ) . It convert steroid metabolizing enzyme liver intestine three active metabolite : two hydroxy-metabolites : 3a-hydroxy-tibolone 3b-hydroxy-tibolone ( exert estrogenic effect vivo present significant amount ) delta-4-isomer ( exert progestagenic androgenic effect , vivo present circulation relatively short period time ( 7 ) ) . The estrogenic metabolite responsible effect hot flush , vagina bone . Tibolone ’ effect endometrium studied number investigator ( 8-14 ) use transvaginal ultrasound ( TVUS ) histology biopsy long-term treatment . With ultrasound observe 6 year treatment endometrial thickness slightly increase ( p &lt; 0.05 , ( 8 ) ) tibolone-users compare control . Dőren et al . ( 9 ) confirm tibolone treatment result slight increase endometrial thickness , different estrogen + norethisterone acetate treatment ( E2+NETA ) . Histology data tibolone use 3 month , show change 90 % subject case endometrial profile show comparable early follicular phase normal cycle ( 15 ) . Even two year tibolone use hyperplasia rarely occur ( 10 ) . In double-blind , randomize control trial , Hammar ( 16 ) show bleed and/or spot episode tibolone user first month use significantly low E2+NETA user , author hypothesize due high progestagenic activity tibolone endometrium compare combined treatment . Our vitro study show indeed tibolone exert progestagenic effect balance progestagenic property estrogenic property tibolone take effect different set gene act genetic network ( 17 , 18 ) . In order investigate whether cell line data tibolone action could confirm vivo , relatively short-term effect tibolone hormonal treatment patient never describe , postmenopausal woman treat 21 day tibolone , estrogen-only , estrogen together progestagen ( estrogen+progestagen ) . From woman serum obtain endometria remove order ass histological immunohistochemical , biochemical ( hormone level ) molecular ( gene expression ) effect relatively short-term tibolone use ( 21-days ) . The overall result may help u obtain insight mechanism action tibolone human endometrium compare reference preparation . Subjects : This study design control clinical trial . Patients visit clinic ( Amphia Hospital Breda , Albert Schweitser Hospital Dordrecht , Erasmus University Medical Center Rotterdam , The Netherlands ) undergo vaginal hysterectomy treatment prolapse , eligible participate study . A description inclusion exclusion criterion current experiment document earlier ( 19 ) . The trial perform period schedule surgery . After informed consent , patient sequentially assign one follow treatment group : Control-group ( hormonal treatment ) ; Tibolone-group ( 2.5 mg tibolone ( Livial , N.V. Organon , Oss , The Netherlands ) administer orally every day , start 21 day prior surgery ) ; E2 group ( 2 mg estradiol administer orally every day , start 21 day prior surgery ) ; E2+MPA-group ( 2 mg estradiol + 5 mg MPA administer orally every day , start 21 day prior surgery ) . The investigator keep blinded patient treatment analysis . The study protocol approve local ethic committee participate hospital . 1. van der Mooren MJ , Kenemans P. Postmenopausal Hormone Therapy : Impact Menopause-Related Symptoms , Chronic Disease Quality Life . Drugs 2004 ; 64:821-836 . 2 . Pickar JH , Yeh I , Wheeler JE , Cunnane MF , Speroff L. Endometrial effect low dos conjugate equine estrogen medroxyprogesterone acetate . Journal Article . Multicenter Study . Randomized Controlled Trial ] Fertil Steril 2001 ; 76:25-31 . 3 . Pickar JH , Yeh IT , Wheeler JE , Cunnane MF , Speroff L. Endometrial effect low dos conjugate equine estrogen medroxyprogesterone acetate : two-year substudy result . Fertil Steril 2003 ; 80:1234-40 . 4 . Anderson GL , Judd HL , Kaunitz AM , Barad DH , Beresford SA , Pettinger M , Liu J , McNeeley SG , Lopez AM ; Women ’ Health Initiative Investigators . Effects estrogen plus progestin gynecologic cancer associate diagnostic procedure : Women ’ Health Initiative randomize trial . JAMA 2003 ; 290:1739-1748 . 5 . Beral V , Million Women Study Collaborators . Breast cancer hormone- replacement therapy Million Women Study . Lancet 2003 ; 362:419-27 . 6 . Kloosterboer HJ . Tibolone : steroid tissue-specific mode action . J Steroid Biochem Mol Biol 2001 ; 76:231-8 . 7 . Timmer CJ , Verheul HA , Doorstam DP . Pharmacokinetics tibolone early late postmenopausal woman . Br J Clin Pharmacol 2002 ; 54:101-6 . 8 . Morris EP , Wilson PO , Robinson J , Rymer JM . Long term effect tibolone genital tract postmenopausal woman . Br J Obstet Gynaecol 1999 ; 106:954-9 . 9 . Dőren M , Rubig A , Coelingh Bennink HJ , Holzgreve W. Impact uterine bleed endometrial thickness : tibolone compare continuous combine estradiol norethisterone acetate replacement therapy . Menopause 1999 ; 6:299-306 . 10 . Volker W , Coelingh Bennink HJ , Helmond FA . Effects tibolone endometrium . Climacteric 2001 ; 4:203-8 . 11 . Wender MC , Edelweiss MI , Campos LS , de Castro JA , Spritzer PM . Endometrial assessment woman use tibolone placebo : 1-year randomized trial 2-year observational study . Menopause 2004 ; 11:423-9 . 12 . Botsis D , Kassanos D , Kalogirou D , Antoniou G , Vitoratos N , Karakitsos P. Vaginal ultrasound endometrium postmenopausal woman symptoms urogenital atrophy low-dose estrogen tibolone treatment : comparison . Maturitas 1997 ; 26:57-62 . 13 . Egarter C , Huber J , Leikermoser R , Haidbauer R , Pusch H , Fischl F , Putz M. Tibolone versus conjugate estrogen sequential progestogen treatment climacteric complaint . Maturitas 1996 ; 23:55-62 . 14 . Rymer J , Fogelman I , Chapman MG . The incidence vaginal bleed tibolone treatment . Br J Obstet Gynaecol 1994 ; 101:53-6 . 15 . Genazzani AR , Benedek-Jaszmann LJ , Hart DM , Andolsek L , Kicovic PM , Tax L. Org OD 14 endometrium . Maturitas 1991 ; 13:243-51 . 16 . Hammar M , Christau S , Nathorst-Boos J , Rud T , Garre K. A double-blind , randomise trial compare effect tibolone continuous combine hormone replacement therapy postmenopausal woman menopausal symptoms.Br J Obstet Gynaecol 1998 ; 105:904-11 . 17 . Blok LJ , De Ruiter PE , Kuhne EC , Hanekamp EE , Grootegoed JA , Smid-Koopman E , Gielen SC , De Gooyer ME , Kloosterboer HJ , Burger CW . Progestogenic effect tibolone human endometrial cancer cell . J Clin Endocrinol Metab 2003 ; 88:2327-34 . 18 . Hanifi-Moghaddam P , Gielen SCJP , Kloosterboer HJ , De Gooyer ME , Sijvers AM , van Gool AJ , Smid M , Morehouse M , Van Wijk FH , Burger CW , Blok LJ . Molecular portrait estrogenic progestagenic action tibolone : Behavior biological network response tibolone . J Clin Endocrinol Metab 2005 ; 90:973-83 . 19 . Klaassens AHA , Van Wijk FH , Hanifi-Moghaddam P , Sijmons B , Ewing PC , Ten Kate-Booij MJ , Kooi GS , Kloosterboer HJ , Blok LJ , Burger CW . Histological immunohistochemical evaluation postmenopausal endometrium 3 week treatment tibolone , estrogen-only , estrogen plus progestagen . Accepted Fertility Sterility , 2006</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Tibolone</mesh_term>
	<mesh_term>Medroxyprogesterone Acetate</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Progesterone</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<mesh_term>Medroxyprogesterone</mesh_term>
	<criteria>Healthy postmenopausal woman uterus . “ Postmenopausal ’ ’ define amenorrhoeic least one year prior screening , amenorrhoeic least six month prior screen serum E2 concentration &lt; 20 pg/ml serum FSH concentration &gt; 40 IU/L screening . If patient use kind steroid hormone therapy prior study , washout period 6 month ( intrauterine progesterone oral estrogen+progestagen combination therapy ) 12 month ( progesterone implant injection inject estrogen+progestagen combination therapy ) apply . 1 . Histological diagnosis local pathologist endometrial biopsy ( Pipelle suction curette ) take treatment , proliferative , secretory menstrual type endometrium , endometrial metaplasia , endometrial endocervical polyp ( ) , endometrial hyperplasia , cancer histological abnormality ( leiomyoma ( ta ) , stromal nodule mesenchymal ( endo ) cervical neoplasia ( ) ) . 2 . Doublelayer endometrium thickness &gt; 4 mm assess transvaginal ultrasound , immediately endometrial biopsy . 3 . History presence malignancy , except successfully treat nonmelanoma skin cancer . 4 . Any unexpected vaginal bleeding follow menopause . 5 . Liver disease , except cholecystectomy . 6 . Abnormal cervical Pap smear test result , abnormal mammography result obtain within one year prior start trial 7 . Deep vein thrombosis , thrombophlebitis , thromboembolic disease , suspicion hereditary predisposition develop venous thromboembolic disease . 8 . Use one follow drug within last two month : hepatic microsomal enzymeinducing anticonvulsant drug know affect interfere pharmacokinetics steroid ( e.g . hydantoin , barbiturate Phenobarbital ( alone combination , Bellergal ) rifampicin , griseofulvin , primidone carbamazepine ) .</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2006</verification_date>
	<keyword>postmenopause</keyword>
	<keyword>endometrium</keyword>
	<keyword>Gene Expression Profiling</keyword>
	<keyword>Histology , Comparative</keyword>
	<keyword>Hormone Replacement Therapy</keyword>
	<keyword>Hormones</keyword>
</DOC>